Understanding the role of bilevel positive airway pressure (BPAP) in pediatric acute asthma exacerbations: A prospective, randomized, double blind, controlled trial.

哮喘仍然是美国儿童住院的三大原因之一。的干预措施 快速逆转支气管阻塞和减少对连续β受体激动剂治疗的需要， 不仅直接使患者受益，而且还减少了急性护理资源的消耗。双水平气道正压 正压通气（BPAP）是一种无创正压通气形式，其可以支撑开放的气道，改善气道压力， 粘液清除，招募肺泡，并增加对持续β受体激动剂治疗的反应性， 远端气道然而，BPAP目前不是NIH儿科急性呼吸道感染管理指南的一部分。 哮喘继发于缺乏高质量的儿科临床试验。这项前瞻性、随机、双 一项盲法对照试验旨在确定早期开始BPAP治疗儿科患者是否有效和安全， 急性中度至重度哮喘急性发作一线治疗失败的儿科急诊科 疗法

Asthma remains one of the top three causes of hospitalization in children in the United States. Interventions that rapidly reverse bronchial obstruction and decrease the need for continuous beta-agonist therapy will not only directly benefit the patient, but also decrease the consumption of acute care resources. Bilevel positive airway pressure (BPAP) is a form of non-invasive positive pressure ventilation that may stent open airways, improve mucous clearance, recruit alveoli, and increase responsiveness to continuous beta-agonist therapy in the small distal airways. However, BPAP is not currently part of the NIH guidelines for the management of pediatric acute asthma secondary to the lack of quality pediatric clinical trials. The goal of this prospective, randomized, double blind, controlled trial is to determine if early initiation of BPAP is effective and safe in pediatric patients presenting to a pediatric emergency department with acute moderate to severe asthma exacerbations who fail first line therapy.